PREOPERATIVE SERUM OXIDATIVE STRESS LEVELS ARE ASSOCIATED WITH ABERRANT PCDH10 METHYLATION IN SERUM AND POOR CLINICAL OUTCOMES IN CURATIVELY RESECTED NODE-NEGATIVE NON-SMALL CELL LUNG CANCER

Respirology ◽  
2017 ◽  
Vol 22 ◽  
pp. 112-113
Keyword(s):  
Oxidative Stress ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Negative ◽  
Preoperative Serum ◽  
Resected Node

scholarly journals Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

Oncotarget ◽  
2014 ◽  
Vol 5 (22) ◽  
pp. 11054-11063 ◽  
Author(s):  
Emilio Bria ◽  
Francesca Di Modugno ◽  
Isabella Sperduti ◽  
Pierluigi Iapicca ◽  
Paolo Visca ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Alternative Splicing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Node Negative ◽  
Resected Node

scholarly journals A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)

JTCVS Open ◽  
2020 ◽  
Vol 4 ◽  
pp. 90-102
Author(s):  
Hideo Kunitoh ◽  
Masahiro Tsuboi ◽  
Masashi Wakabayashi ◽  
Morihito Okada ◽  
Kenji Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Node Negative ◽  
Phase Iii Study ◽  
Resected Node

P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S368 ◽  
Author(s):  
G. Clark ◽  
P. Cagnoni ◽  
M. Ptaszynski ◽  
M. Hamilton ◽  
P. Santabárbara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib

2021 ◽  
pp. 030089162110478
Author(s):  
Gianluca Taronna ◽  
Alessandro Leonetti ◽  
Filippo Gustavo Dall’Olio ◽  
Alessandro Rizzo ◽  
Claudia Parisi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Clinical Variable ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Egfr Mutated

Introduction: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Some osimertinib-related interstitial lung diseases (ILDs) were shown to be transient, called transient asymptomatic pulmonary opacities (TAPO)—clinically benign pulmonary opacities that resolve despite continued osimertinib treatment—and are not associated with the clinical manifestations of typical TKI-associated ILDs. Methods: In this multicentric study, we retrospectively analyzed 92 patients with EGFR-mutated NSCLC treated with osimertinib. Computed tomography (CT) examinations were reviewed by two radiologists and TAPO were classified according to radiologic pattern. We also analyzed associations between TAPO and patients’ clinical variables and compared clinical outcomes (time to treatment failure and overall survival) for TAPO-positive and TAPO-negative groups. Results: TAPO were found in 18/92 patients (19.6%), with a median follow-up of 114 weeks. Median onset time was 16 weeks (range 6–80) and median duration time 14 weeks (range 8–37). The most common radiologic pattern was focal ground-glass opacity (54.5%). We did not find any individual clinical variable significantly associated with the onset of TAPO or significant difference in clinical outcomes between TAPO-positive and TAPO-negative groups. Conclusions: TAPO are benign pulmonary findings observed in patients treated with osimertinib. TAPO variability in terms of CT features can hinder the differential diagnosis with either osimertinib-related mild ILD or tumor progression. However, because TAPO are asymptomatic, it could be reasonable to continue therapy and verify the resolution of the CT findings at follow-up in selected cases.

Sign in / Sign up

Export Citation Format

Share Document